Matching articles for "Juvmo"
Tavapadon (Juvmo) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • November 9, 2026; (Issue 1767)
Tavapadon (Juvmo – Abbvie), an oral nonergot partial
dopamine agonist, has been approved by the FDA for
treatment of Parkinson's disease...
Tavapadon (Juvmo – Abbvie), an oral nonergot partial
dopamine agonist, has been approved by the FDA for
treatment of Parkinson's disease (PD).